Peptron announced on the 24th that it has applied for a building modification permit to expand the total floor area of its second plant at the Osong Bio Park in North Chungcheong Province to approximately 2.5 times its previous size.

■ Total Floor Area Expanded from 12,000 sq m to 30,000 sq m The modification permit involves a design change to comprehensively expand the production and support facilities of the second plant, with the core change being the increase of the total floor area from approximately 12,000 sq m to around 30,000 sq m. In simple terms, this represents an expansion of roughly 2.5 times compared to the original. The adjustment is interpreted as a move to scale up the facility beyond the initially planned size.

■ Responding to Pipeline Expansion... Targeting Over 10-Fold Increase in Production Capacity The Osong second plant has been pursued as a production base to respond to Peptron's pipeline expansion. The company has already completed a paid-in capital increase and the issuance of exchangeable bonds to finance the new plant facilities, and has previously stated its goal of increasing production capacity by more than 10-fold compared to current levels. The second plant will be designed as a dedicated pharmaceutical production facility meeting current Good Manufacturing Practice (cGMP) standards, and the company is currently undergoing the building permitting process with Cheongju City prior to the start of construction.

■ Detailed Design Withheld as Trade Secret In this disclosure, the company stated that the detailed design and facility composition related to the modification permit constitute important business information pertaining to production technology and operational strategy, making it difficult to disclose specifics. Therefore, it is currently unknown which product lines the expanded production facilities will be allocated to and what the detailed purposes of the support facilities will be.

■ Future Checkpoints The factors to watch going forward are as follows. First, whether the building modification permit is actually approved and when, the contractor selection process, and whether the construction start and completion schedules proceed as originally planned. In addition, the progress of the smart depot technology assessment that Peptron is conducting with U.S.-based Eli Lilly, as well as whether a formal contract will be signed, are key points to watch as they are directly linked to the timing of the new plant's operation and the allocation of production capacity. As the company has indicated, major future developments will be disclosed sequentially in accordance with relevant regulations, making it necessary to monitor subsequent disclosures.

[This article was written with the assistance of AI. Investors need to approach with caution by verifying subsequent information such as additional disclosures or earnings announcements. This article is intended only as reference material for investment decisions and does not recommend the purchase or sale of any specific stock.]